Ipsen S.A. (I7G.F)

Compare

104.90

0.00

(0.00%)

At close: April 4 at 12:54:13 PM GMT+2

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, maturing in March 2032. Following the disclosure of the Investment Grade ratings with BBB- from S&P and Baa3 from Moody’s, both with a stable outlook, this transaction was very well r

GlobeNewswire 17 days ago

IPSEF

IPSEY
0.00%
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen’s Executive Leadership Team (ELT) and report directly to Chief Executive Officer David Loew. In this newly created role, she will lead Ipsen’s global neurotoxins franchise, overseeing strategy and execution across both therapeutic and aesthetic indication

GlobeNewswire 24 days ago

IPSEF

IPSEY
0.00%
Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 28 February 2025 83,814,526 Gross total* of voting rights: 131,933,057 Net tot

GlobeNewswire 30 days ago

IPSEF

IPSEY
0.00%
Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...

Ipsen SA (IPSEF) reports robust financial performance with a 9.9% sales increase and strategic pipeline developments, despite facing competitive pressures.

GuruFocus.com last month

IPSEY
0.00%
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% in Neuroscience, and 7.3% in Oncology; Somatuline® (lanreotide) sales grew by 5.6%, while all other products, excluding Somatuline, achieved double-digit sales growth at 12.2%FY 2024 core operating income of €1,109m, growing 10.8% as reported, with core operating margin of 32.6% of total sales Conti

GlobeNewswire last month

IPSEF

IPSEY
0.00%
Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 January 2025 83,814,526 Gross total* of voting rights: 131,933,045 Net tota

GlobeNewswire last month

IPSEF

IPSEY
0.00%
Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 December 2024 83,814,526 Gross total* of voting rights: 131,939,858 Net tot

GlobeNewswire 2 months ago

IPSEF

IPSEY
0.00%
Ipsen - Half year statement - 2024 12 31

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF Boulogne-Billancourt (France), January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account: 24,701 shares€2,635,980.25 It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account: 12,751 shares€3,137,934.80 Between July

GlobeNewswire 2 months ago

IPSEF

IPSEY
0.00%
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 30 November 2024 83,814,526 Gross total* of voting rights: 132,129,451 Net tot

GlobeNewswire 3 months ago

IPSEF

IPSEY
0.00%
Ipsen and Biomunex enter agreement for cancer therapy

Biomunex could receive up to $610m, including upfront and milestone payments.

Pharmaceutical Technology 3 months ago

IPSEY
0.00%
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potentialBMX-502 is a bispecific antibody engaging MAIT cells, a subset of non-conventional T cells, and targeting the clinically validated tumor antigen GPC3 to kill cancer cells PARIS, FRANCE; 03 December 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX

GlobeNewswire 3 months ago

IPSEF

IPSEY
0.00%
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Familial Intrahepatic Cholestasis (PF

GlobeNewswire 4 months ago

IPSEF

IPSEY
0.00%
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. in October 2024 PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association for

GlobeNewswire 4 months ago

IPSEF

IPSEY
0.00%
Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 October 2024 83,814,526 Gross total* of voting rights: 132,135,791 Net tota

GlobeNewswire 4 months ago

IPSEF

IPSEY
0.00%
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. YTD 2024 YTD 2023 % change Q3 2024 Q3 2023 % change €m €m Actual CER1 €m €m Actual CER1 Oncology 1 829,8 1 744,1 4,9% 5,8% 604,0 574,5 5,1% 5,6% Neuroscience 536,4 489,0 9,7% 11,8% 181,9 164,8 10,4% 10,1% Rare Disease 129,7 76,0 70,7% 71,3% 50,8 33,2 53,1% 54,4% Total Sales 2 495,9 2 309,1 8,1% 9,

GlobeNewswire 5 months ago

IPSEF

IPSEY
0.00%
Ipsen receives its second Shingo Prize for operational excellence

Ipsen is the first pharma company in the world to receive Shingo Prizes for two sites producing treatments for patientsIpsen’s first Shingo Prize was received by its production site in Signes, France in 2020, followed by the site in Dublin, Ireland todayThe Shingo Prize represents the highest standard of operational excellence in the world PARIS, FRANCE, 14 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Dublin, Ireland production site has received the Shingo Prize for

GlobeNewswire 5 months ago

IPSEF

IPSEY
0.00%
Ipsen SA (IPSEF) (H1 2024) Earnings Call Highlights: Strong Sales Growth Amidst Challenges

Ipsen SA (IPSEF) reports a robust 9.5% sales increase, while navigating Somatuline sales decline and rising R&D costs.

GuruFocus.com 5 months ago

IPSEY
0.00%
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)30 September 202483,814,526Gross total* of voting rights: 132,140,937Net total**

GlobeNewswire 5 months ago

IPSEF

IPSEY
0.00%
Ipsen’s Elafibranor gains MHRA approval for PBC treatment

The endorsement follows a placebo-controlled study involving 161 adults with PBC.

Pharmaceutical Technology 5 months ago

IPSEY
0.00%
Ipsen’s Iqirvo wins European approval for primary biliary cholangitis

The approval sets up a showdown between Iqirvo and Intercept’s PBC treatment Ocaliva.

Pharmaceutical Technology 6 months ago

IPSEY
0.00%

Performance Overview

Return	I7G.F	CAC 40 (^FCHI)
YTD	-4.64%	-1.43%
1-Year	-0.40%	-10.75%
3-Year	-7.32%	+8.08%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ipsen S.A. (I7G.F)

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - Half year statement - 2024 12 31

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen and Biomunex enter agreement for cancer therapy

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

Ipsen receives its second Shingo Prize for operational excellence

Ipsen SA (IPSEF) (H1 2024) Earnings Call Highlights: Strong Sales Growth Amidst Challenges

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen’s Elafibranor gains MHRA approval for PBC treatment

Ipsen’s Iqirvo wins European approval for primary biliary cholangitis

Performance Overview